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the evidence base. This evidence base was then investigated, in
order to assess ﬁndings to answer the study question. RESULTS:
In total, 52 papers were listed; four were relevant for inclusion.
two of these articles were retrospective cohort studies and two
were based on budget-impact models. Costs were presented as
medical charges; medication possession ratio (MPR) and/or per-
sistence rates were measures of non-compliance; osteoporosis
medications included bisphosphonates and HRT. US Medical
charges were 35% higher in non-compliers compared with
compliers and total monthly charges were 76% higher. Based
on modelling, persistence levels with bisphosphonates of <50%
at 12 months results in almost 20,000 excess fractures over a
10 year period and 22 M per annum fracture-related costs to
the UK NHS. CONCLUSION: The evidence base in this area is
limited. However, it indicates that medication non-compliance
and failure to persist has substantial ﬁnancial consequences
within the ﬁeld of osteoporosis management. This conclusion is
consistent with the evidence available from both observation
studies and modelling analyses in the US and UK health care
systems. Further work is warranted to review other disease
areas, and to further synthesise the data to provide an
estimated aggregate of the international cost of medication
non-compliance.
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OBJECTIVES: To assess the cost-effectiveness of an ongoing
osteoporosis screening campaign in Belgian women aged from
50 to 69 years. METHODS: A cost-effectiveness analysis was
performed using a decision tree analysis and a microsimulation
Markov model. We compared the screening campaign versus no
intervention. Screening campaign consisted of quantitative
ultrasound screening by mobile units. For all individuals having
a positive result, three possibilities are observed: no follow-up,
direct treatment or screening with DXA (dual energy X-ray
absorptiometry). Most of the individuals having a positive
DXA result received Alendronate therapy. Sensitivity analyses
and simulations were based on model parameters (discount
rates, fracture costs, fracture risks, fracture disutility, mortality
excess and treatment speciﬁcities), characteristics of screening
campaign (screening efﬁcacy, prevalence of osteoporosis and
screening cost), number of clinical risk factors and persistence
level. RESULTS: In the base case (with 100% persistence), the
cost per QALY gained for the screening strategy was €44,927.
Sensitivity analyses showed that this value was affected by per-
sistence level (€81,921 for realistic persistence). The efﬁciency
greatly improved if we only screen individuals with one clinical
risk factor (€23,265) or more (from €15,377 for two clinical
risk factors to cost-saving for four clinical risk factors). We also
showed that pre-screening using quantitative ultrasound was
more efﬁcient than universal DXA screening if the cost of quan-
titative ultrasound was less than €14.8 per patient screened.
CONCLUSION: The base case result was near to threshold
value of €45,000 per QALY gained. Consequently, it was dif-
ﬁcult to interpret the results and to qualify the campaign efﬁ-
ciency. Our recommendations to improve it are to target
screening on individuals with one or more clinical risk factors,
to generalize DXA for all individuals having a positive quanti-
tative ultrasound result, to treat all individuals having a posi-
tive DXA result and to improve compliance and adherence to
therapy.
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OBJECTIVES: To compare effectiveness, medical costs and cost-
effectiveness of zoledronic acid, one single yearly infusion, versus
usual care in post-menopausal osteoporosis in France, taking
into account compliance proﬁles. METHODS: Twelve simula-
tion based models were built to investigate 3 types of fractures:
vertebral (VF), non-vertebral (NVF) and hip (HF), comparing 2
groups: zoledronic acid and usual care. Two effectiveness
assumptions have been tested to handle the issue of clinical trial
population heterogeneity: 1) speciﬁc agent effectiveness values,
and 2) same standard effectiveness range of values for all active
agents. Direct medical costs include drug costs, medical visits,
monitoring and fracture medical management. Compliance has
been integrated into the model with the assumption that non-
compliant patients have the placebo effectiveness range of values.
Conservative compliance range of rates for active agents has been
expressed in accordance with the literature and expert opinion,
from 40% to 60% for oral drugs and from 50% to 100% for
Zoledronic acid single yearly infusion. A full probabilistic sensi-
tivity analysis has been carried out to generate costs, effectiveness
and cost-effectiveness over 3 years, with conﬁdence intervals.
Statistical tests were performed to calculate potential signiﬁcant
differences. RESULTS: Using the second assumption (2), the
zoledronic acid strategy leads to less vertebral, non-vertebral
and hip fractures than usual care: (88.0% vs. 85.7%,
89.4% vs. 88.2% and 97.2% vs. 95.4%) respectively, (p <
0.001). Zoledronic acid generates lower total medical costs
versus usual care in all types of fracture (p < 0.001): 944€ vs.
995€ (VF), 1164€ vs. 1245€ (NVF) and 1156€ vs. 1261€ (HF).
CONCLUSION: Zoledronic acid is the dominant strategy,
regardless of fracture type or effectiveness assumptions. A simu-
lation modeling approach seems appropriate to investigate
various effectiveness values from heterogeneous clinical trials.
Isolating the compliance effect allows us to conﬁrm the added
value of a once yearly infusion of zoledronic acid 5 mg.
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OBJECTIVES: To evaluate the cost effectiveness of zoledronic
acid 5 mg once yearly compared to the leading branded com-
pounds in the UK, i.e. Fosamax once weekly, Actonel once
weekly, Bonviva once monthly, and Protelos once daily in
patients with postmenopausal osteoporosis. METHODS: The
cost effectiveness model applied tracks the model NICE used in
their appraisal document for the cost effectiveness of treatments
of osteoporosis in postmenopausal women at increased risk of
fracture. Lifetime costs and quality adjusted life years (QALYs)
were calculated assuming ﬁve years of treatment. Relative risks
of fracture protection were obtained from the HORIZON-PFT
trial for zoledronic acid 5 mg, meta-analyses from NICE reviews
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